Physician profile
Parham Mora
NPI 1417915679
$16,306.97
in general payments reported to CMS, 2019-2025
22 companies · $266 in 2025
The $266 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,303 · 2020: $4,688 · 2021: $229 · 2022: $4,466 · 2023: $957 · 2024: $398 · 2025: $266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,621.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,620.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $12,756.70 | 2019-2023 | Da Vinci Surgical System |
| Applied Medical Resources Corporation | $1,175.99 | 2019 | |
| Asensus Surgical, INC. | $763.05 | 2019 | |
| Teleflex LLC | $424.73 | 2023-2025 | Titan Sgs Standard Gastric Stapler, Titan Sgs Bailout Chuck |
| Novo Nordisk INC | $190.49 | 2024-2025 | Wegovy |
| Davol INC. | $151.43 | 2019-2021 | |
| Conmed Corporation | $135.24 | 2019-2023 | Airseal |
| Ethicon US, LLC | $93.78 | 2023 | Echelon; Endopath |
| Paratek Pharmaceuticals, INC. | $87.64 | 2024 | Nuzyra |
| Ardelyx, INC. | $78.96 | 2024 | Ibsrela |
| Tela Bio, INC. | $77.74 | 2024-2025 | Ovitex 2s, Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Acell, INC. | $72.45 | 2020 | |
| Medical Device Business Services, INC. | $71.92 | 2019 | |
| Genzyme Corporation | $46.69 | 2024 | |
| Currax Pharmaceuticals LLC | $43.87 | 2022-2025 | Contrave |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| W. L. Gore & Associates, INC. | $28.01 | 2020 | |
| Vertex Pharmaceuticals Incorporated | $23.10 | 2025 | |
| Medela LLC | $20.86 | 2020 | |
| Phathom Pharmaceuticals, INC. | $19.16 | 2024 | Voquezna |
| Endogastric Solutions, INC | $16.40 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.89 | 2021 | |
| Janssen Biotech, INC. | $13.87 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parham Mora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.